Two Onc Docs Acute Myeloid Leukemia (AML) 2024 x Dr. Catherine Lai Part 2
8 snips
Jun 24, 2024 Dr. Catherine Lai from UPenn discusses AML treatment options, including chemotherapy regimens based on core binding factors, variations in toxicity, and advancements like Gemtuzumab. She also explores recovery strategies, repeatable marrow biopsies, and different treatment approaches based on risk categories and patient fitness levels. The podcast ends with key takeaways on AML diagnosis criteria, induction regimens, specific treatment options for mutations, and the importance of seeking feedback.
AI Snips
Chapters
Transcript
Episode notes
Choose Therapy By Physiologic Fitness
- Do assess physiologic fitness rather than chronological age when choosing AML therapy.
- For fit patients use 7+3 as standard and add gemtuzumab for core binding factor leukemias.
Differentiate FLT3 ITD Versus TKD
- Distinguish FLT3 ITD from TKD because targeted options differ.
- Midostaurin covers both ITD and TKD while quizartinib targets ITD only for newly diagnosed patients.
Watch Gemtuzumab Toxicity Timing
- Avoid gemtuzumab near planned transplant due to liver toxicity risk.
- Expect increased cytopenias and higher risk of sinusoidal obstructive syndrome after gemtuzumab.